Anixa Biosciences (ANIX) shares were up over 10% in recent Wednesday trading after the company said it received a notice of allowance from the US Patent and Trademark Office for its breast cancer vaccine technology.
The patent, licensed exclusively from Cleveland Clinic, broadens the scope of immunogenic compositions in the vaccine. It covers methods of immunizing patients using a protein found in breast tissue and certain breast cancers, Anixa said Wednesday.
Price: 2.63, Change: +0.25, Percent Change: +10.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.